1401222-64-7 Usage
Description
4-(Morpholinosulfonyl)phenylboronic acid pinacol ester is an organic compound that serves as a key intermediate in the synthesis of various pharmaceutical compounds. It is characterized by its unique chemical structure, which includes a boronic acid pinacol ester group and a morpholinosulfonyl group attached to a phenyl ring. 4-(Morpholinosulfonyl)phenylboronic acid pinacol ester is known for its reactivity and utility in the development of therapeutic agents.
Uses
Used in Pharmaceutical Industry:
4-(Morpholinosulfonyl)phenylboronic acid pinacol ester is used as a synthetic intermediate for the development of pyridopyrazine derivatives. These derivatives are known for their potential applications in the treatment of various proliferative cell diseases, such as cancer and other abnormal cell growth conditions. The compound's unique structure allows for the creation of diverse therapeutic agents with targeted effects on specific cellular pathways.
In the synthesis process, 4-(Morpholinosulfonyl)phenylboronic acid pinacol ester can be utilized to form new bonds and functional groups, enabling the production of a wide range of bioactive molecules. Its reactivity and versatility make it a valuable component in the design and development of novel pharmaceuticals aimed at treating proliferative cell diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 1401222-64-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,0,1,2,2 and 2 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1401222-64:
(9*1)+(8*4)+(7*0)+(6*1)+(5*2)+(4*2)+(3*2)+(2*6)+(1*4)=87
87 % 10 = 7
So 1401222-64-7 is a valid CAS Registry Number.
1401222-64-7Relevant articles and documents
JNK INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
-
, (2022/04/03)
Provided are a compound shown in formula (I) below, and racemates, stereoisomers, tautomers, isotopic markers, solvates, polymorphs and oxynitrides of the compound, or a pharmaceutically acceptable salt thereof, wherein same can be used as JNK inhibitors. Also provided are a method for preparing the compound shown in formula (I), a pharmaceutical composition comprising the compound shown in formula (I), and the use of the compound shown in formula (I) for preparing drugs, wherein the drugs are used for treating diseases which can be treated by inhibiting JNK activity.
SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF
-
Paragraph 00451, (2015/01/16)
The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structural Formula (A) : or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula (A), or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.
IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS
-
Page/Page column 25, (2008/06/13)
The compounds of formula (I) in which R1, R2, R3, R4, R5 and A have the meanings as given in the description are novel effective iNOS inhibitors.
